Zydus Lifesciences reported a 36% decline in net profit to ₹939.8 crore for Q1 FY27, even as revenue grew 22% to ₹8,017 crore. The bottom line was impacted by higher operating expenses and one-time costs, including legal settlements. Investors are tracking how the company manages margin pressure while integrating its recent US acquisitions.
Zydus Lifesciences Ltd. saw a contrasting performance in its first-quarter results for FY27, with strong top-line growth overshadowed by a sharp decline in profitability. The pharmaceutical company reported a 22% increase in revenue from operations, which reached ₹8,017 crore. However, net profit fell by 36% year-on-year to ₹939.8 crore.
The decline in profit was largely due to pressure on operating margins and higher costs. The company’s EBITDA, a key measure of core operating profit, fell by 7.6% to ₹1,929.4 crore. Consequently, EBITDA margins contracted to 24.1% from 31.8% in the same quarter last year. According to the company, this dip in profitability was influenced by exceptional items, including provisions made for severance compensation and legal settlements.
The business performance varied significantly across segments. The domestic India formulations business remained a bright spot, posting a 20% revenue jump to ₹1,815.8 crore. The consumer wellness segment also showed strong momentum, with revenue climbing 67% to ₹1,429.2 crore, fueled by performance in its skin, hair, and nutrition brands. Conversely, the North America formulations business, which accounts for the largest share of revenue, faced headwinds and recorded a 3% decline in revenue compared to the previous year.
Strategically, Zydus is attempting to shift its focus toward higher-value products to offset the competitive pressure in the US generic drug market. During the quarter, the company finalized the acquisition of Assertio Holdings for approximately $166.4 million. This move is aimed at strengthening its US specialty pharmaceutical presence. Furthermore, the company reached a milestone with the launch of Nufymco, its first biosimilar in the US market.
For investors, the primary monitorable in the coming quarters will be the company’s ability to improve profit margins. The integration of recent acquisitions and the successful scaling of its specialty drug portfolio, particularly the planned launch of Saroglitazar in the US, will be critical. Additionally, the market will track whether the North American business can stabilize or return to growth, given the ongoing pricing pressure in the competitive US generics sector. The company's future performance will depend on balancing these expansion costs with the need to restore profitability to previous levels.